Back
V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) acts as an activating ligand for monocytes and is upregulated in systemic lupus erythematosus
Scientific Publications
April 2025
Tasnia Chowdhury • Kirsty Waddington • Wiktoria Jozefowska • Neil Ashley • Gabriela Pirgova • Chantal Hargreaves • James Heward • Neil Stokes • Rachael Nimmo • Stephen Harrison
More News from Nucleome
News
November 2025
Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell
Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living...
Read more
News
August 2025
Succession plan for CSO
Oxford, UK, 5 August 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biote...
Read more
News
May 2025
Press release: Appointment of Bhavna Hunjan as Chief Business Officer (CBO)
Oxford, UK, 27 May 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechno...
Read more
Video
May 2025
Nucleome – Using Human Genetics to Understand Human Disease
Video explaining how Nucleome Therapeutics are developing breakthrough genomics technologies focusse...
Read more
News
November 2024
High resolution genetic mapping has identified a novel disease target for rheumatoid arthritis
Despite clinicians having a variety of therapeutic options for rheumatoid arthritis (RA), very few p...
Read more
Scientific Publications
November 2024
Illuminating the Dark Genome to enable drug discovery from human genetics
The Dark Genome Symposium Heward J, Smith J, Owers L, Davidson B, James-Bott A, Repapi E, Hertweck A...
Read more
Scientific Publications
November 2024
High resolution genetic mapping has identified a novel disease target for rheumatoid arthritis
The Dark Genome Symposium Hargreaves C, Jozefowska W, Lucchesi D, Maio S, Hertweck A, Repapi E, Sutt...
Read more
News
October 2024
Nucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune disease
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi...
Read more
Video
September 2024
Biotech TV interview with CEO Mark Bodmer
New CEO Mark Bodmer describes the value in understanding the non-coding region of the genome and how...
Read more
News
July 2024
Nucleome Therapeutics appoints Mark Bodmer as Chief Executive Officer
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomi...
Read more